Almirall, S.A. today announced its intention to file a Marketing Authorization Application with the European Medicines Agency (EMEA) for its once-daily long acting muscarinic antagonist Eklira® (aclidinium bromide) in early 2010, for the maintenance bronchodilator treatment and symptom control of COPD.
The details can be read here.
No comments:
Post a Comment